- ISIN
- IE000GID8VI0
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 25, 2021
Highlights
- Market Cap
- $1.92B
- Enterprise Value
- $1.68B
- EPS (TTM)
- -$0.91
- Gross Profit (TTM)
- -$268.00K
- EBITDA (TTM)
- -$58.38M
- Year Range
- $11.32 - $31.00
- Target Price
- $36.50
- ROA (TTM)
- -20.49%
- ROE (TTM)
- -21.42%
- Avg. Volume (1M)
- 281K
- Avg. Volume Value (1M)
- $7.88M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GHRS Performance Chart
GH Research PLC (GHRS) is up 121.0% since the beginning of the year. At $28 per share, GHRS is trading 9.5% below its 52-week high of $31. Investors who bought $1,000 worth of GHRS shares 5 years ago would now be looking at an investment worth $1,425.
Loading charts...
Compare this symbol against anything
Returns By Period
GH Research PLC (GHRS) has returned 121.02% so far this year and 104.29% over the past 12 months.
GH Research PLC
- 1D
- -1.09%
- 1M
- 3.92%
- 6M
- 79.25%
- YTD
- 121.02%
- 1Y
- 104.29%
- 3Y*
- 25.65%
- 5Y*
- 7.34%
- 10Y*
- —
- ALL TIME*
- 4.90%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
GHRS Monthly Returns History
Based on dividend-adjusted daily data since Jun 25, 2021, GHRS's average daily return is +0.16%, while the average monthly return is +2.06%. At this rate, an investment would double in approximately 2.8 years.
Historically, 55% of months were positive and 45% were negative. The best month was Jan 2025 with a return of +51.4%, while the worst month was Sep 2024 at -36.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, GHRS closed higher 48% of trading days. The best single day was Feb 3, 2025 with a return of +69.7%, while the worst single day was Aug 8, 2022 at -24.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.31% | -5.17% | -5.32% | 46.02% | 16.85% | 12.05% | 4.43% | 121.02% | |||||
| 2025 | 51.43% | -4.43% | 8.88% | -13.51% | 26.10% | 1.33% | 17.80% | -5.99% | 5.93% | 0.14% | 5.87% | -16.23% | 81.43% |
| 2024 | 30.86% | 17.00% | 20.05% | 2.81% | 28.56% | -17.25% | 6.35% | -15.32% | -36.29% | 21.08% | 10.25% | -21.61% | 20.69% |
| 2023 | -8.54% | 7.76% | -16.60% | 5.13% | 33.33% | 5.94% | 10.83% | -19.16% | -5.46% | -27.26% | -14.64% | -7.05% | -40.33% |
| 2022 | -27.22% | -2.83% | 10.85% | -20.39% | -31.18% | -0.40% | 11.82% | 39.34% | -25.27% | -12.39% | 7.47% | -11.15% | -58.34% |
| 2021 | -1.23% | -9.34% | 11.02% | 0.87% | 14.73% | 4.58% | -11.86% | 6.05% |
Benchmark Metrics
GH Research PLC has an annualized alpha of 31.72%, beta of 1.01, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since June 25, 2021.
- This stock participated in 140.29% of S&P 500 Index downside but only 116.03% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 31.72%
- Beta
- 1.01
- R²
- 0.04
- Upside Capture
- 116.03%
- Downside Capture
- 140.29%
Return for Risk
Risk / Return Rank
GHRS ranks 84 for risk / return — above 84% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for GH Research PLC (GHRS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GHRS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.09 | ||
| Sortino ratioReturn per unit of downside risk | +0.17 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.25 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 3.50 | 2.00 | +1.50 |
| Martin ratioReturn relative to average drawdown | 8.97 | 8.49 | +0.48 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the GH Research PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GH Research PLC was 81.15%, occurring on Dec 18, 2023. Recovery took 631 trading sessions.
The current GH Research PLC drawdown is 3.64%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-81.15%Dec 2023 | 2y 1mo | 2y 6mo | 4y 7moNov 2021 - Jun 2026 | — |
-40.46%Oct 2021 | 1mo 12d | 8d | 1mo 20dSep 2021 - Oct 2021 | — |
-26.62%Jul 2021 | 25d | 1mo 12d | 2mo 7dJul 2021 - Sep 2021 | — |
-12.50%Jun 2021 | 1d | 6d | 6dJun 2021 - Jul 2021 | — |
-11.02%Jul 2026 | 13d | 3d | 16dJun 2026 - Jul 2026 | — |
Drawdown Indicators
| GHRS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -81.15% | -56.78% | -24.37% |
Max Drawdown (1Y)Largest decline over 1 year | -27.41% | -9.10% | -18.31% |
Max Drawdown (3Y)Largest decline over 3 years | -60.78% | -18.90% | -41.88% |
Max Drawdown (5Y)Largest decline over 5 years | -81.15% | -25.43% | -55.72% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -3.64% | -1.58% | -2.06% |
Average DrawdownAverage peak-to-trough decline | -51.58% | -10.70% | -40.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.00% | 2.14% | +8.86% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of GH Research PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how GH Research PLC is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GHRS in comparison with other companies in the Biotechnology industry. Currently, GHRS has a P/B value of 6.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GHRS
Add GH Research PLC to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GHRS